INTRODUCTION 7 6
Inhaled corticosteroids (ICS) are commonly used in the management of chronic diseases of the 7 7 airways due to their impact on airway inflammation. ICS reduce the rate of exacerbations, 7 8 decrease respiratory symptoms, improve lung function and quality of life in patients with determine whether preventative therapy is necessary to reduce BMD decline and the risk of The objective of this study was to examine the impact of ICS on BMD loss in postmenopausal 1 0 2 women with asthma or COPD in routine clinical practice. We hypothesized that in women with 1 0 3 asthma or COPD, after controlling for disease severity and patient characteristics, BMD is lower 1 0 4 in those exposed to ICS compared with unexposed women, and that BMD declines more rapidly 1 0 5 with increasing exposure to ICS. The province of Manitoba, Canada, provides universal health care to its population of 1.3 million 1 0 9 residents (as of 2016) 15 . The administrative needs of maintaining the public health care system 1 1 0 have resulted in the creation of centralized health care databases, which comprehensively capture 1 1 1 information about hospital discharges, physician billing claims, prescription medication 1 1 2 dispensations as well as demographics, registration and vital statistics. These databases have low 1 1 3 rates of missing data and high validity [16] [17] [18] . The current study was based on bone densitometry to all bone densitometry services in the province since 1990 (completeness and 1 1 7 accuracy≥99%) 20 . The BMD registry was linked at the individual level with other population- Repository via an encrypted personal health number. The study was approved by the Human This retrospective cohort study had both cross-sectional and longitudinal components. displays the schematic presentation of the study design. The study population consisted of 1 2 5 women who were at least 40 years of age, had continuous health care coverage for at least 3 1 2 6 years prior to undergoing their first BMD test, and had a previous diagnosis of asthma or COPD. These diagnoses were identified by the presence of one or more hospitalizations or two or more 1 2 8 physician claims with diagnostic codes for asthma or COPD, during the 3-year period prior to the 1 2 9
first BMD test. Asthma-specific inpatient and outpatient encounters were determined based on 1 3 0 International Classification of Diseases, 9 th Edition (ICD-9) codes of 493.x, and ICD-10 codes of assurance is under strict supervision by a medical physicist 19 . Instruments were cross-calibrated 1 4 2 and no clinically significant differences were detected 20 The instruments used for this study BMD was measured at the femoral neck, total hip, and lumbar spine (L1-4). The primary site for 1 4 7 the cross-sectional analysis was the femoral neck as this is the reference standard for description in T-scores (i.e., the number of standard deviations above or below the mean of a healthy young We examined the longitudinal loss in BMD between the first and second scans as the change in 1 5 5 T-scores divided by the time in years between the two scans where the second scan was at least 1 5 6 12 months after the baseline examination. The primary site for the longitudinal analysis was the 1 5 7 total hip since it has the best test-retest precision and is the least affected by age-related 1 5 8 degenerative artifact 24 . All exposure measures were obtained from the comprehensive provincial pharmacy system using 1 6 1 data from the Drug Program Information Network (DPIN) 17 . The use of ICS was measured in 1 6 2 multiple ways. Cumulative dispensed days (primary exposure) and total dispensed quantity (mcg for the cross-sectional analysis. For the longitudinal analyses, the dispensed days between the 1 6 5 two BMD measurements, measured by medication possession ratio (MPR) was used. MPR was 1 6 6 defined as the ratio of days that a patient was on medication divided by the total number days 1 6 7 observed for that patient (a value between 0 and 1). As such, its definition is independent of the 1 6 8 length of the time window. As a secondary longitudinal exposure, we also measured total 1 6 9 dispensed quantity of ICS between the two scans, which was normalized for time (divided by the 1 7 0 time interval between the two scans). For each exposure definition, based on the tertiles of exposure, ICS use was classified into four 1 7 2 categories: none, lowest-, middle-and highest tertile. The reference category was none (no use). All analyses were performed with Dell Statistica (Version 13.0, Dell Inc. 2015). A 2-sided P-1 7 5 value of 0.05 was set as the threshold for assessing statistical significance. For the cross-sectional analysis, we used generalized linear models with analysis of covariance to 1 7 7 estimate the association between the history of ICS use and the levels of BMD at baseline, with 1 7 8 parallel analyses performed for each of the three different BMD measurement sites. We used 1 7 9
BMD T-score as the outcome and tertiles of ICS use prior to the first BMD scan as the main diagnosis, based on ICD codes) assessed prior to the index date from administrative data. We products, raloxifene, teriparatide). In addition, to account for the potential confounding effect of 1 8 7 disease severity, we also adjusted for total number of dispensed days (in tertiles) of oral We tested the interaction effects of disease diagnosis and ICS use on BMD loss in an exploratory 1 9 1 analysis. In a sensitivity analysis we replaced days of ICS use with total dispensed quantity of 1 9 2 ICS (beclamethasone-equivalents) as the alternative exposure. in BMD (expressed as T-score SD/year) between the two consecutive BMD tests, with parallel 1 9 6 analyses performed for changes in all three BMD measurement sites. We conducted a sensitivity 1 9 7 analysis in which we repeated the longitudinal analysis for the subgroup of women who did not 1 9 8 have any estrogen or osteoporosis medication exposure during the observation period. The cross-sectional sample included 6,561 female patients aged 40 years and above, including 2 0 2 63% with a primary diagnosis of COPD and 37% with asthma, respectively (Table 1 ). The ICS prior to BMD testing and were divided into 3 tertiles based on total days of usage (lowest 2 0 5 tertile: 1-155 days of use, middle: 156-719 days, highest: above 720 days). The mean T-scores of 2 0 6 hip, femoral neck and lumbar spine were -1.0, -1.5 and -1.1, respectively. Based on the lowest 2 0 7 score across the sites, osteoporosis was prevalent in 31% of patients at baseline. COPD, chronic obstructive pulmonary disease. T-scores at baseline. Prior ICS exposure was associated with lowered baseline T-scores for the 2 1 6 femoral neck (p=0.005) and total hip (p=0.002), but not for the lumbar spine (p=0.12). Specifically, the highest tertile of prior ICS days was associated with lowered T-scores compared were not significantly different from non-users across three sites. The effects of prior ICS 2 2 1 exposure on baseline T-scores did not significantly differ between the COPD and asthma patients 2 2 2 (p=0.52 for the interaction term between disease and ICS use). (bottom) lumbar spine. Drug use was measured as the total number of dispensed days of ICS 2 2 7 before 1 st BMD scan and was categorized into tertiles, with the reference group being "No Use". Lowest tertile, 1-155 days of ICS use, middle tertile, 156-719 days, highest tertile, above 720 In the secondary analysis, we changed the main exposures from the total days to the total 2 3 2 dispensed quantity of prior ICS use. Results were consistent for all three sites: compared to no 2 3 3 use, the highest tertile of ICS quantities (>840,000mcg of beclomethasone equivalent) was 2 3 4 associated with lower baseline T-scores for the femoral neck (-0.09 [95% CI: -0.16, -0.02, 2 3 5 p=0.006]) and total hip (-0.15 [95% CI: -0.23, -0.06, p<0.001]), but not for lumbar spine 2 3 6 (p=0.11). From the initial sample, we identified 1,807 women (59% COPD, 41% asthma) who received a tertile of ICS MPR versus no use was associated with a significant decline in total hip T-score (-2 4 9 0.024 SD/year [95% CI: -0.040, -0.008], p=0.003), whereas the lowest and middle tertiles of We used administrative health data of a well-defined geographic area with complete health care 2 7 0 coverage linked with a bone densitometry database to examine the cross-sectional and 2 7 1 longitudinal impact of ICS use on BMD in postmenopausal women with previously diagnosed 2 7 2 asthma or COPD. In the cross-sectional analysis, the highest tertile of ICS use (previous use of 2 7 3 more than 720 days) was found to negatively impact BMD at the total hip and femoral neck after longitudinal analyses, receiving ICS for more than 50% of the time between the two scans was 2 7 6 associated with a modest decline in total hip bone density. Overall, these associations are 2 7 7 considered weak. In the cross-sectional analysis, only patients with two or more years of prior 2 7 8 exposure to ICS had baseline bone density lower than the non-users, with the T-score reduction 2 7 9 much less than one standard deviation for the femoral neck (SD=0.14) and total hip (SD=0.13). patients with over 50% adherence to ICS (highest tertile) would need to be sustained for over 40 2 8 2 years to produce one standard deviation reduction in total hip BMD. Our findings are in line with other studies that have found an association between ICS therapy 2 8 4 and minor BMD loss 5-9 , and this response is generally observed to be dose-dependent 5,6,9 . In 2 8 5 general, the patients in our study were receiving low dose ICS therapy; 85% of patients were 2 8 6 dispensed less than 5 puffs (100mcg/puff) of beclomethasone-equivalent per day, although actual 2 8 7 medication intake is likely even lower 28 . Similar to Wong et al. 6 , we observed a dose-dependent inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 19. Leslie WD, Metge C. Establishing a regional bone density program: lessons from the
